ImmunityBio, Inc.
IBRX
$2.81
$0.1355.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.51M | 7.21M | 5.95M | 990.00K | 40.00K |
| Total Other Revenue | 8.00K | 346.00K | 152.00K | 57.00K | 40.00K |
| Total Revenue | 16.52M | 7.55M | 6.11M | 1.05M | 40.00K |
| Cost of Revenue | 58.00K | -- | -- | -- | -- |
| Gross Profit | 16.46M | 7.55M | 6.11M | 1.05M | 40.00K |
| SG&A Expenses | 33.65M | 42.93M | 36.92M | 50.45M | 42.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.95M | 76.95M | 86.36M | 100.38M | 95.24M |
| Operating Income | -64.43M | -69.40M | -80.25M | -99.33M | -95.20M |
| Income Before Tax | -129.90M | -59.18M | -85.75M | -134.58M | -134.13M |
| Income Tax Expenses | -234.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -129.67M | -59.18M | -85.75M | -134.58M | -134.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.00K | 17.00K | 23.00K | 20.00K | 21.00K |
| Net Income | -129.65M | -59.16M | -85.73M | -134.56M | -134.11M |
| EBIT | -64.43M | -69.40M | -80.25M | -99.33M | -95.20M |
| EBITDA | -60.60M | -65.26M | -75.80M | -94.93M | -90.64M |
| EPS Basic | -0.15 | -0.08 | -0.12 | -0.20 | -0.20 |
| Normalized Basic EPS | -0.10 | -0.05 | -0.08 | -0.12 | -0.12 |
| EPS Diluted | -0.15 | -0.09 | -0.14 | -0.20 | -0.20 |
| Normalized Diluted EPS | -0.10 | -0.05 | -0.08 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 853.16M | 733.20M | 695.90M | 686.94M | 672.83M |
| Average Diluted Shares Outstanding | 853.16M | 734.54M | 697.96M | 686.94M | 672.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |